Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BMY, LLY, ENDP, and AGN Early Briefing and Review

BMY
BMY, LLY, ENDP, and AGN Early Briefing and Review

StockCall.com Provides Stock Research on Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Pharmaceuticals Holdings Inc., and Allergan Inc.

New York City, New York -- (April 30, 2013)

Major drug manufacturers faced significant challenges in 2012 as they saw patents on many of their blockbuster drugs expire, which led to increasing competition from generic drugs. This trend is expected to continue over the next few years. The “patent cliff” is expected to have a major impact on major drug companies’ top-line. The key for these companies will be to build a strong product pipeline. Healthcare stocks ended mostly higher in Monday’s trading session, tracking gains in the broad market which closed at record high levels. Among the major movers in the sector were Bristol Myers Squibb Co. (NYSE: BMY), Eli Lilly & Co. (NYSE: LLY), Endo Health Solutions Inc. (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN).StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at

www.stockcall.com/report

Shares of Bristol Myers Squibb & Co. slipped in Monday’s trading session even as the broad market posted significant gains. The stock closed 0.92% lower at $39.91 on volume of 6.72 million after trading between $39.81 and $40.28. Shares of BMY have fallen more than 3.70% in the last three sessions. Despite the recent losses, the stock is still up more than 24.80% for the year, outperforming the broad market. Bristol Myers Squibb’s shares are currently trading 6.90% below their 52-week high.Sign up for the free report on BMY at

www.StockCall.com/BMY043013.pdf

Shares of Eli Lilly & Co. also slipped in trading on Monday. The stock fell to an intra-day low of $55.79 before finishing the day 0.80% lower at $56.01 on above average volume of 4.85 million. Despite the pullback, Eli Lilly’s shares are currently trading close to their 52-week high of $58.40. The stock has jumped more than 14.60% so far in 2013 as compared to a gain of more than 11.70% for the S&P 500. The company’s shares are currently trading above their 50-day and 200-day moving averages.LLY free technical report can be accessed by signing up at

www.StockCall.com/LLY043013.pdf

Shares of Endo Health Solutions Inc. slipped on Monday; however, the losses were limited. The stock ended the day 0.03% lower at $36.45 on volume of 1.81 million. Shares of the company have seen a series of highs over the past one month. The stock has gained 18.50% in the last one month. Year-to-date, it has gained nearly 39%, outperforming the S&P 500. However, the stock’s MACD has just crossed below the signal line which suggests that market sentiment has turned bearish on the stock.Free report on ENDP can be accessed by registering at

www.StockCall.com/ENDP043013.pdf

Shares of Allergan Inc. edged higher in Monday’s trading session, extending their gains from the previous trading sessions. The stock closed 1.52% higher at $113.68 on volume of 899,570 after touching an intra-day high of $113.76. Allergan’s shares have gained more than 2.30% in the last three sessions. The stock is currently trading close to its 52-week high of $116.45. Year-to-date, shares of AGN have gained nearly 24%, outperforming the S&P 500. The company’s shares currently face resistance at around $115.Register withStockCall and download the research on AGN for free at

www.StockCall.com/AGN043013.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today